The Correlation of Two Different Real-Time PCR Devices for the Analysis of CYP2C19 Pharmacogenetic Results
Authors:
- Alba Alonso LlorenteALAlba Alonso Llorente
- Josefa Salgado GarridoJGJosefa Salgado Garrido
- Oscar Teijido HermidaOHOscar Teijido Hermida
- Fabricio González AndradeFAFabricio González Andrade
- Alberto Valiente MartínAMAlberto Valiente Martín
- Ana Fanlo VillacampaAVAna Fanlo Villacampa
- Jorge Vicente RomeroJRJorge Vicente Romero
Open Access
- 6 November 2023
- journal article
- research article
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 91 (4) , 51
Abstract
CYP2C19 is a highly polymorphic gene responsible for the metabolism of commonly used drugs. CYP2C19*1, the wild-type allele, is associated with normal enzyme activity, whereas CYP2C19*2 and CYP2C19*17 lead to null and increased enzyme activity, respectively. The use of different instruments to perform the same pharmacogenetic tests should not affect the reliability of the results reported to clinicians, as required by the ISO 15189 standard. Genotyping assays allowed for the identification of gene variants corresponding to the CYP2C19*2 and CYP2C19*17 haplotypes in 44 selected samples. Each sample was analyzed in duplicate using the Thermo Fisher Taqman Drug Metabolism probes CYP2C19*2: c_25986767_70 (rs4244285) and CYP2C19*17: c_469857_10 (rs12248560). The experiments were performed on two widely used types of real-time PCR analyzers: ABI PRSIM™7500 and QuantStudioTM12KFlex (both from Applied Biosystems, Thermofisher). The data were analyzed in a Thermo Fisher Cloud facility. The analysis was performed independently by two qualified professionals. Both different instruments and analysts’ interpretations were consistent in identifying the native homozygous, heterozygous, and mutant homozygous variants for CYP2C19*2 and CYP2C19*17. The results provided by both the primary and backup analyzers showed a perfect correlation. This would allow for the use of the backup analyzer in case the main one is not available.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacogenetics and Forensic Toxicology: A New Step towards a Multidisciplinary ApproachToxics, 2021
- CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health SystemClinical and Translational Science, 2020
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole TherapyClinical Pharmacology & Therapeutics, 2016
- Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infectionsExpert Review of Anti-infective Therapy, 2016
- Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of VoriconazoleCurrent Fungal Infection Reports, 2015
- Applications of CYP450 Testing in the Clinical SettingMolecular Diagnosis & Therapy, 2013
- A model for results comparison on two different biochemistry analyzers in laboratory accredited according to the ISO 15189Biochemia Medica, 2009
- Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Laboratory errors: How to improve pre- and post-analytical phases?Biochemia Medica, 2007
- A Rapid and Simple Detection of Genetic Defects Responsible for the Phenotypic Polymorphism of Cytochrome P450 2C19.Biological and Pharmaceutical Bulletin, 1999